Direkt zum Inhalt
Merck
Alle Fotos(1)

Wichtige Dokumente

Gesamtdokumentation anzeigen

R8404

Sigma-Aldrich

Rufinamid

≥98% (HPLC), powder

Synonym(e):

1-[(2,6-Difluorphenyl)-methyl]-1H-1,2,3-triazol-4 carboxamid

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise
Alle Fotos(1)

About This Item

Empirische Formel (Hill-System):
C10H8F2N4O
CAS-Nummer:
106308-44-5
Molekulargewicht:
238.19
MDL-Nummer:
MFCD00865314
UNSPSC-Code:
12352200
PubChem Substanz-ID:
24724595
NACRES:
NA.77

Qualitätsniveau

100

Assay

≥98% (HPLC)

Form

powder

Farbe

white

Löslichkeit

DMSO: 9 mg/mL

Ersteller

Novartis

Lagertemp.

−20°C

SMILES String

NC(=O)c1cn(Cc2c(F)cccc2F)nn1

InChI

1S/C10H8F2N4O/c11-7-2-1-3-8(12)6(7)4-16-5-9(10(13)17)14-15-16/h1-3,5H,4H2,(H2,13,17)

InChIKey

POGQSBRIGCQNEG-UHFFFAOYSA-N

Angaben zum Gen

human ... SCN10A(6336) , SCN11A(11280) , SCN1A(6323) , SCN2A(6326) , SCN3A(6328) , SCN4A(6329) , SCN5A(6331) , SCN7A(6332) , SCN8A(6334) , SCN9A(6335)

Suchen Sie nach ähnlichen Produkten? Aufrufen Leitfaden zum Produktvergleich

Anwendung

Rufinamide has been used to test its analgesic effect on neuropathic pain in spared nerve injury (SNI) model.

Biochem./physiol. Wirkung

Rufinamide may elicit inhibition of the sodium channels and block action potential generation. This property makes it an antiepileptic drug for treating epilepsy disorders like Lennox-Gastaut syndrome.
Broad-spectrum anticonvulsant.

Leistungsmerkmale und Vorteile

This compound was developed by Novartis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Diagnostische Implikationen

Effective therapy for partial seizures in adults and childhood seizures in Lennox-Gastaut syndrome.

Piktogramme

Health hazardExclamation mark
GHS08,GHS07

Signalwort

Warning

Gefahreneinstufungen

Carc. 2 - Repr. 2 - STOT SE 3

Zielorgane

Central nervous system

Lagerklassenschlüssel

11 - Combustible Solids

WGK

WGK 3

Flammpunkt (°F)

Not applicable

Flammpunkt (°C)

Not applicable

Hier finden Sie alle aktuellen Versionen:

Analysenzertifikate (COA)

Lot/Batch Number
0000248700
0000248701
106M4613V
124M4601V
021M4615V

Die passende Version wird nicht angezeigt?

Wenn Sie eine bestimmte Version benötigen, können Sie anhand der Lot- oder Chargennummer nach einem spezifischen Zertifikat suchen.

Suche nach COA

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Kunden haben sich ebenfalls angesehen

Slide 1 of 7

1 of 7

Lacosamid -Lösung 1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®

Supelco

L-029

Lacosamid -Lösung

vibrant-m

Y0001982

Lacosamid

Levetiracetam ≥98% (HPLC)

Sigma-Aldrich

L8668

Levetiracetam

Teriflunomid ≥98% (HPLC)

Sigma-Aldrich

SML0936

Teriflunomid

Retigabin analytical standard

Supelco

90221

Retigabin

Gabapentin solid

Sigma-Aldrich

G154

Gabapentin

Streptavidin Sepharose™ Hochleistung Cytiva 17-5113-01, pack of 5 mL

GE17-5113-01

Streptavidin Sepharose™ Hochleistung

Shahin Hakimian et al.
Expert opinion on pharmacotherapy, 8(12), 1931-1940 (2007-08-19)
Rufinamide (1-[2,6-difluorobenzyl]-1H-1,2,3-triazole-4-carboxamide) is a new anti-epileptic drug with a novel triazole derivative structure. The suspected mechanism of action is limitation of sodium-dependent action potentials, thought to result in a membrane stabilizing effect. Rufinamide is extensively metabolized in the liver by
Alberto Verrotti et al.
Pediatric neurology, 44(5), 347-349 (2011-04-13)
Rufinamide is a new orally active antiepileptic drug that has been found to be effective in the treatment of partial seizures and drop attacks associated with Lennox-Gastaut syndrome. We performed a quantitative analysis of the efficacy of this new antiepileptic
Maria G Dahlin et al.
Neuropediatrics, 43(5), 264-270 (2012-09-04)
We examined the influence of age and type of concomitant antiepileptic drugs (AEDs) on the pharmacokinetics of rufinamide (RUF) as well as its efficacy and safety in 51 children with refractory epilepsy. In a retrospective noninterventional survey, dose-to-concentration ratios of
Isabelle Mourand et al.
Epilepsia, 54(1), e5-e8 (2012-07-12)
Rufinamide (RUF) is a novel antiepileptic drug considered as second-line therapy in the treatment of Lennox-Gastaut syndrome. Treatment-emergent adverse events (AEs) have consisted mainly of drowsiness, irritability, vomiting, and loss of appetite. RUF is considered as a "weight-neutral" drug. We
C von Stülpnagel et al.
European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society, 16(5), 459-463 (2012-01-24)
We evaluated the long-term efficacy and tolerability of the orphan drug rufinamide (RUF) in children with pharmacoresistant myoclonic-astatic epilepsy (MAE, Doose syndrome). This was a retrospective European multicenter study on eight patients who had started an intention-to-treat trial of RUF
Alle zugehörigen Dokumente anzeigen

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.